Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan. J Pediatr 2007 Feb;150(2):140-5
Date
01/24/2007Pubmed ID
17236890DOI
10.1016/j.jpeds.2006.08.028Scopus ID
2-s2.0-33846198883 (requires institutional sign-in at Scopus site) 137 CitationsAbstract
OBJECTIVES: To assess the accuracy of 18F-fluoro-L-dihydroxyphenylalanine ([18F]-DOPA) PET scans to diagnose focal versus diffuse disease and to localize focal lesions in infants with congenital hyperinsulinism.
STUDY DESIGN: Twenty-four infants with hyperinsulinism unresponsive to medical therapy were studied. Patients were injected intravenously with [18F]-DOPA, and PET scans were obtained for 1 hour. Images were coregistered with abdominal CT scans.
RESULTS: The diagnosis of focal or diffuse hyperinsulinism was correct in 23 of the 24 cases (96%) and equivocal in 1 case. [18F]-DOPA PET identified focal areas of high uptake of radiopharmaceutical in 11 patients. Pathology results confirmed that all 11 had focal adenomatosis, and the locations of these lesions matched the areas of increased [18F]-DOPA uptake on the PET scans in all of the cases.
CONCLUSIONS: [18F]-DOPA PET scans were 96% accurate in diagnosing focal or diffuse disease and 100% accurate in localizing the focal lesion. These results suggest that [18F]-DOPA PET imaging should be considered in all infants with congenital hyperinsulinism who need to have pancreatectomy.
Author List
Hardy OT, Hernandez-Pampaloni M, Saffer JR, Suchi M, Ruchelli E, Zhuang H, Ganguly A, Freifelder R, Adzick NS, Alavi A, Stanley CAAuthor
Mariko Suchi MD, PhD Associate Professor in the Pathology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Confidence IntervalsCongenital Hyperinsulinism
Dihydroxyphenylalanine
Female
Humans
Infant
Infant, Newborn
Injections, Intravenous
Male
Pancreas
Positron-Emission Tomography
Prospective Studies
Risk Assessment
Sensitivity and Specificity
Severity of Illness Index
